By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Amoy Diagnostics this week received marketing approval from China's State Food and Drug Administration for its EGFR and BRAF tests for clinical use.

The AmoyDx EGFR assay tests for mutations in the tyrosine kinase domain associated with sensitivity to the kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). According to the Ziamen, China-based firm, the test also detects the T790M mutation that is associated with resistance to treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.